Abstract 25
Variation in non-muscle-invasive bladder cancer recurrence after transurethral resection surgery between sites is independent of tumor factors: Results from the RESECT study (NCT05154084)
Forts Gabor1, Kevin Gallagher1, Nikita Bhatt1, Keiran Clement1, Eleanor Zimmermann1, Sinan Khadourni1, Meghana Kulkarni1, Thines Anbarasan2, Alexander Ng1, Alexander Light1, Aqua Asif1, Vinson Chan1, Arjun Nathan3, Sabrina Ross1, Tim O’Brien1, Steven MacLennan1, Matthew Nielsen1, Paramaranthan Mariappan1, Veeru Kasivisvanathan1, RESECT study global collaborators (BURST)
1Department of Health Policy and Management, Harvard TH Chan School of Public Health, Boston, MA; 2Department of Urology, Western General Hospital, Edinburgh, UK; 3Department of Urology, Norfolk and Norwich University Hospital, Norwich, UK; 4Department of Urology, NHS Greater Glasgow Clyde, UK; 5University Hospitals Plymouth, UK; 6University of Aberdeen, Health Services Research Unit, UK; 7St. Georges University Hospital London, UK; 8Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; 9University College London, Division of Surgery and Interventional Science, UK; 10Royal Free London NHS Foundation Trust, UK; 11Department of Surgery and Cancer, Imperial College London, London, UK; 12University College London, Division of Surgery and Interventional Science, UK; 13School of Medicine, Faculty of Medicine, University of Leeds, Leeds, UK; 14Academic Department of Surgery, University of Cambridge, UK; 15Guy’s and St. Thomas’ NHS foundation trust, London, UK; 16Academic Urology Unit, University of Aberdeen, UK; 17Department of Urology, University of North Carolina School of Medicine, Chapel Hill, NC; 18Department of Urology, Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, Edinburgh, UK.

Introduction: We aimed to determine if there is significant variation in early recurrence after transurethral resection (TURBT) surgery between sites taking part in the RESECT study (NCT05154084) after accounting for tumor characteristics.

Methods: We conducted an international, multicenter, observational study. A mixed-effects logistic regression model with tumor size, tumor number, tumor grade, tumor stage as fixed effects, and site as a random effect was fitted. Cases with first, presumed non-muscle-invasive bladder cancer (NMIBC) undergoing TURBT were included. Cases were excluded if first check followup had not been completed. Sites were excluded if they did not have at least 10 cases with first check followup. Local and/or national approvals or ethical exemptions were obtained prior to commencing the study at participating sites.

Results: After exclusions, 186 sites (UK: 80; Europe: 59; North America: 18; Asia: 17; Africa: 7; South America: 3; Oceania: 2) contributing a total 4597 cases (average 25 cases) were included. Median recurrence rate per site was 12% (IQR 0–22) for low-grade tumors and 27% (IQR 13–42) for high-grade tumors (Figure 1). After controlling for tumor size, number, stage, and grade (all significantly and independently associated with early recurrence) (Table 1), there was significant residual variation attributable to site (p=0.0001, intra-class correlation, 0.1). Adjustment for sites improved the regression model from an area under the receiver operating characteristic curve of 0.66 to 0.74. Initial analysis of surgical and perioperative practice showed wide variation; a mean of 75% (IQR 66–92) of cases per site had detrusor muscle resection and 42% (IQR 17–58) had use of single instillation chemotherapy. Other differences in operative and perioperative practice were identified through surveys.

Conclusions: There is significant variation in the early recurrence rate of NMIBC after TURBT surgery between sites that could not be explained by currently understood tumor features. We have identified differences in surgical technique and perioperative practice that may impact this, and further investigation is warranted to understand how these factors impact recurrence rates.

Funding: The RESECT study is supported by unrestricted grants from Karl Storz, Photocure, and Medac Pharma.
Abstract 26
Intravesical contrast-enhanced magnetic resonance imaging (ICE-MRI) of superficial and invasive bladder cancer
Pradeep Iyengar, Marc Connell, Chan-Hong Moon, Biatta Shalosh, Christopher Chermansky, Rajiv Dhir, Jodi Maranchie
University of Pittsburgh, Pittsburgh, PA

Introduction: The critical role of staging in bladder cancer prognosis and higher rates of understaging with traditional imaging and transurethral resection (TUR) propels the search for alternatives. Here, we describe the premise and promise of ICE-MRI to discriminate superficial from invasive bladder cancer and inflammatory lesions.

Methods: Twenty-one subjects in the age range of 62–90 years with the suspicion of bladder cancer on cystoscopy were recruited for NCT04369560 and 13 (12 males and one female) subjects consented for ICE-MRI prior to TUR or cystectomy. Bladder was scanned before and after instillation via 14 Fr urethral straight tip catheter of 50 mL gadobutrol (20mM) and ferumoxytol (0.1mM) using T2-weighted turbo spin echo and 3D T1-weighted fast low-angle shot (FLASH) at Siemens Biograph 3T.

Results: Multislice T1-weighted ICE-MRI over 92s (repetition/echo time [TR/TE] 4000/100 ms) in voxel volume of 0.625x0.625x3 mm3 with slice thickness 3 mm and number of signal averages (NSA=2) produced dark lumen with clear demarcation of enhanced regions of interest (ROI) in seven quadrants of bladder wall, and then 3D-FLASH acquisition over 23.30 s at each flip angle of 3° to 22°, with constant TR/TE of 5.24/1.86 ms mapped T1 of ROIs in voxel volume of 0.67x0.67x1 mm3. Larger extracellular space and lower cellularity of inflammatory lesions (3/13) than the histopathologically proven superficial, urothelial cancer lesions (9/13) elicited higher contrast-enhancement from instilled gadobutrol diffusing down the concentration gradient passively along tight junctions (paracellular) and exclusively into extracellular space available in ROI. Deeper submucosal enhancement predicted MBc, later confirmed by histopathology of cystectomy specimen. While catheterization evoked brief discomfort in all subjects, no one complained of any additional discomfort from luminal retention of the contrast mixture for ~30 min in ICE-MRI.

Conclusions: ICE-MRI capitalizes on the differences in perturbed tight junctions, cellularity, and extracellular space modifying gadobutrol diffusion for differential enhancement of superficial, MBc and inflammatory lesions. Further studies are warranted to determine if ICE-MRI can be a non-surgical surveillance tool for enhancement of superficial, MIBC and inflammatory lesions. Further studies are warranted to determine if ICE-MRI can be a non-surgical surveillance tool for enhancement of superficial, MIBC and inflammatory lesions. Future studies are warranted to determine if ICE-MRI can be a non-surgical surveillance tool for enhancement of superficial, MIBC and inflammatory lesions.

Funding: CA252390

Abstract 27
Pharmacologic inhibition of endogenous hydrogen sulfide production in an intravesical murine model of bladder cancer
Sydney Relouw1,2, George Dugbarley3,4, Natasha Knier1, Francisco Martinez-Santiesteban, Melissa Huynh2,5, S. M. Mansour Haeryfar6, Alp Sener1,3,7
1Department of Microbiology & Immunology, Western University, London, ON, Canada; 2Department Pharmacology, Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, Legon, Accra; 3Department of Surgery, Western University, London, ON, Canada; 4Department of Medical Biophysics, Western University, London, ON, Canada; 5Robarts Research Institute, Western University, London, ON, Canada; 6Lawson Health Research Institute, London, ON, Canada; 7Division of Clinical Immunology & Allergy, Department of Medicine, Western University, London, ON, Canada

Introduction: Current intravesical bladder cancer treatment paradigms have limited therapeutic impact, requiring investigation of novel therapies. Recent evidence suggests hydrogen sulfide (H2S), an endogenous gaseous signaling molecule, mediates cancer progression. Preliminary in-vitro data demonstrated significant attenuation of mouse and human bladder cancer cell viability by an H2S-producing enzyme inhibitor and significant potentiation by an H2S donor, alluding to a role of H2S in the progression of bladder cancer. Thus, this study investigates the effect of inhibiting endogenous H2S production on bladder cancer tumor progression with or without chemotherapy in vivo.

Methods: A murine intravesical bladder cancer model was subjected to mono- and dual intravesical therapies consisting of an H2S donor; an H2S-producing enzyme inhibitor; and conventional chemotherapy. Magnetic resonance imaging (MRI) depicted tumor burden prior to and subsequent to intravesical therapy, and these images were used to evaluate tumor progression.

Results: Current findings, as portrayed in Figure 1, demonstrate a noticeable downward trend in tumor growth following treatment with the H2S inhibitor. This effect was partially abrogated by H2S donor administration compared to the control. Furthermore, dual therapy with the H2S inhibitor and chemotherapy demonstrated a downward trend in tumor growth compared to chemotherapy alone and significantly suppressed tumor growth compared to H2S inhibitor monotherapy (p<0.0001) and the control (p<0.0001), resulting in tumor regression.

Conclusions: These findings suggest that inhibition of endogenous H2S production shows antineoplastic effects and H2S inhibition together with conventional chemotherapy produces a synergistic effect. Thus, H2S could be a potential therapeutic target in bladder cancer treatment.

Funding: Canadian Urological Association Scholarship Foundation
Abstract 28
Assessing health disparities in non-muscle-invasive bladder cancer through the Ontario Marginalization Index
Maximiliano Ringué, Jethro C.C. Kwong, Anna Ali, Yashan Chelliahpillia, Hafish Khurrum, Soomin Lee, Nicole Bodnarev, Venkata L. S. Chaudhury, Andrew Feifer, John W. Gray, Michael A. L Safety, Nicholas M. Roberts, John A. Chang, Andrea Necchi, Wonderful Hong, Jethro C.C. Kwong, Andrew Feifer, John W. Gray, Michael A. L Safety, Nicholas M. Roberts, John A. Chang, Andrea Necchi, Wonderful Hong, Jethro C.C. Kwong, Andrew Feifer, John W. Gray, Michael A. L Safety, Nicholas M. Roberts, John A. Chang, Andrea Necchi, Wonderful Hong, Jethro C.C. Kwong, Andrew Feifer, John W. Gray, Michael A. L Safety, Nicholas M. Roberts, John A. Chang, Andrea Necchi, Wonderful Hong. Sexual Health Clinic, Toronto, ON, Canada; 2Department of Urology, University of Toronto, Toronto, ON, Canada; 3Department of Oncology, University of Toronto, Toronto, ON, Canada; 4Research Internship, Trillium Health Partners, Mississauga, ON, Canada; 5Department of Urology, Chonnam National University Medical School, Gwangju, Korea; 6Department of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA; 7Department of Urology, Amsterdam, the Netherlands; 8Department of Urology, York, ON, Canada; 9Institute for Better Health, Trillium Health Partners, Mississauga, ON, Canada; 10Department of Urology, University of Toronto, Toronto, ON, Canada; 11Department of Medical Oncology, Atrium Health Levine Cancer Institute, Charlotte, NC; 12MidLantic Urology/Solaris Health, Bala Cynwyd, PA; 13Department of Urology, Ghent University Hospital, Ghent, Belgium; 14AZ Sint-Jan Brugge-Oostendse, Bruges, Belgium; 15Janssen Research Development, Spring House, PA; 16Janssen Research Development, High Wycombe, U.K.; 17Regina Elena National Cancer Institute, Department of Urology, Rome, Italy.

Introduction: Socio-economic levels have shown association with diagnostic cancer stage, treatment patterns and overall mortality; however, the impact of marginalization status on NMIBC outcomes remains unclear. The Ontario Marginalization Index (ON-Marg) is a tool for studying health inequality using four dimensions: residential instability, material deprivation, dependency, and ethnic concentration. This study aimed to assess the association between marginalization and non-muscle-invasive bladder cancer (NMIBC) outcomes for patients treated at a Canadian center that serves one of the most diverse communities worldwide, with ≥50% of its constituents identifying as immigrants.

Methods: An ongoing retrospective chart review (2005–2022) of NMIBC patients from a regional cancer center in Ontario was conducted; with preliminary analysis of 154 patients. Marginalization status, clinical and disease features, treatment, compliance, and recurrence, progression, and overall survival (OS) were collected. Marginalization status was calculated using ON-Marg. Grouping as follows: G1=low marginalization (ON-Marg levels 1–2); G2=high marginalization (ON-Marg level 3–5). Differences in tumor stage at diagnosis and treatment compliance were assessed using Chi-squared tests. Time to event analysis were assessed by Kaplan-Meier curve analysis.

Results: Sixty-one patients (40%) were G1 and 93 (60%) were G2. At diagnosis, pT1 was present in 36% and 41% of G1 and G2 (p=0.8), respectively, and high-grade tumor in 71% of G1 and 80% of G2 (p=0.2). Rates of recurrence were 53% vs. 71% (p=0.09), high-risk recurrence 48% vs. 56% (p=0.5), and any progression 28% vs. 42% (p=0.08) for G1 vs. G2, respectively (Figure 1). No differences observed in treatment compliance, OS, or cancer-specific survival.

Conclusions: In a marginalized patient population, higher grade and stage tumors were more common. This may be associated with delayed presentation, or other mitigating non-measured factors. Further investigation with a larger cohort is ongoing to fully understand the relationship between marginalization, social determinants of health, and prognosis in NMIBC patients.

Abstract 29
First results from SunRISe-1 in patients with bacillus Calmette-Guérin unresponsive, high-risk non-muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone
Joseph Jacobs, Siomak Daneshmand, Michel S. van der Heijden, Andrea Necchi, Evangelia Xylina, David S. Morris, Philipp Spiegelhalder, Daniel Zainfeld, Taek Won Kang, Justin T. Matulay, Laurence H. Belkoff, Karel Decoestecker, Harm Arenszen, Sholakia Hampras, Shu Jin, Christopher J. Cutie, Hussein Sweiti, Katherine Stromberg, Jason Martin, Giuseppe Simone.
1Upstate Medical University, Department of Urology, Syracuse, NY; 2Department of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA; 3Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, the Netherlands; 4Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy; 5Department of Urology, Bichat-Claude Bernard Hospital, Assistance-Publique-Hôpitaux de Paris, University of Paris Cité, Paris, France; 6Urology Associates, Nashville, TN; 7Urologic Neandertal, Gemeinschaftspraxis für Urologie, Mettmann, Germany; 8Urology San Antonio, San Antonio, TX; 9Department of Urology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, Korea; 10Atrium Health Levine Cancer Institute, Charlotte, NC; 11MidLantic Urology/Solaris Health, Bala Cynwyd, PA; 12Department of Urology, Ghent University Hospital, Ghent, Belgium; 13AZ Sint-Jan Hospital Brugge-Oostendse, Bruges, Belgium; 14Janssen Research Development, Clinical Oncology, Raritan, NJ; 15Janssen Research Development, Clinical Oncology, Lexington, MA; 16Janssen Research Development, Spring House, PA; 17Janssen Research Development, High Wycombe, U.K.; 18Regina Elena National Cancer Institute, Department of Urology, Rome, Italy.

Introduction: Patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to intravesical bacillus Calmette-Guérin (BCG) have limited treatment options. TAR-200 is a novel intravesical drug delivery system that provides sustained local release of gemcitabine into the bladder. Cetrelimab is an anti-PD1 agent. SunRISe-1 is an ongoing phase 2 study (NCT04640623) evaluating efficacy and safety of TAR-200 + cetrelimab (cohort 1 [C1]), TAR-200 alone (C2), or cetrelimab alone (C3) in patients with BCG-unresponsive HR NMIBC (carcinoma in situ [CIS]), who are ineligible/decline radical cystectomy. We report preliminary results from SunRISe-1, providing data from C2 and C3.

Methods: Patients ≥18 years with histologically confirmed CIS ± papillary disease (T1, high-grade Ta) who completed adequate BCG ≥12 months before enrollment and with ECOG performance status 0–2 were randomized to C1, C2, or
C3. TAR-200 was dosed Q3W through week 24, then Q12W until week 96. Cetrelimab was dosed through week 78. Cystoscopy; centrally read urine cytology, CT/MRI, and centrally read TURBT (bladder biopsy) were performed at baseline and prespecified time points to assess disease response. The primary endpoint is overall complete response (CR) rate. Secondary endpoints include duration of response, overall survival, pharmacokinetics, quality of life, safety, and tolerability.

**Results:** As of May 25, 2022, 13 patients in C2 and 13 in C3 (median age 71.5 years [range 51–88]) received treatment. The efficacy evaluable set comprised eight patients in C2, and eight in C3. Centrally confirmed CR by urine cytology and/or biopsy was 88% (95% CI 47–100) in C2 and 38% (9–76) in C3. Median CR duration of response for C2 and C3 was not reached after median follow-up of 12.7 (C2) and 13.8 (C3) months. All 13 patients in C2 who achieved CR remained in CR, with three ongoing responses ≥6 months (range 7.7–9.4 months). Eleven patients (85%) in C2 and eight (62%) in C3 had treatment-emergent adverse events (TEAEs); most were grade 1–2. Most common TEAEs were pollakiuria (39%), micturition urgency (39%), and non-infective cystitis (39%) in C2; fatigue (23%) and lipase increased (23%) in C3. One patient (8%) in C2 and two patients (15%) in C3 had treatment-related Gr ≥3 TEAEs. One serious TEAE (myocarditis) occurred in C3.

**Conclusions:** First results from SunRISe-1 show promising CR rate and safety profile with TAR-200 monotherapy. Cetrelimab results are consistent with other anti-PD(L)1 treatment in this setting. Preliminary efficacy and safety data support the continued study in NMIBC.

**Funding:** Janssen Research Development

---

**Abstract 30**

**Does betulinic acid, a natural anti-cancer agent, target metabolic programming in bladder cancer?**

Anirban Ganguly, Stephanie Daugherty, Kears Healy, Jonathan Beckett, Anthony Kanai, Pradeep Tyagi

University of Pittsburgh, Pittsburgh, PA

**Introduction:** Betulinic acid (ALS 357) obtained from the bark of white birch (Betula alba), is a well-known tumor-selective drug, which underwent phase I clinical testing for melanoma (NCT00346502). Betulinic acid is known to affect mitochondrial potential but the mechanism for its tumor selectivity is unknown. While rapid proliferation consumes glucose at higher rate, cancer cells also rewire their metabolism amid nutrient scarcity to metabolize fatty acids and cholesterol for proliferation. Hence, we reasoned that the structural similarities with cholesterol may underlie the tumor selectivity of betulinic acid and accordingly examined the effect of glucose supplementation on the antiproliferative effect of betulinic acid on bladder cancer.

**Methods:** Cell culture: T24 bladder transitional carcinoma cells and non-cancerous, non-immortalized human urothelial cells (HBDEC) were procured from ATCC. T24 cells were cultured in McCoy’s 5a medium supplemented with 10% FBS, whereas HBDEC cells were maintained in bladder epithelial cell basal medium supplemented with the bladder epithelial growth kit (both purchased through ATCC). In addition, both cell lines were also grown in respective media after supplementation with 10% glucose. MTT assay: Cells were plated on 96 well plates at a concentration of 5000 cells/well and allowed to grow overnight. The cells were then treated with increasing amounts of betulinic acid for 18 hours both in normal and high glucose media. IC50 was determined by MTT assay.

**Results:** The IC50 of betulinic acid on T24 cancer cells was nearly two-fold lower than on HBDEC cells without glucose supplementation. While the doubling time of HBDEC and IC50 of betulinic acid was only slightly reduced with 10% glucose supplementation, T24 cells became resistant to the cytotoxic effect of betulinic acid, and IC50 nearly doubled to affirm the role of Warburg effect and higher glucose consumption for fueling the rapid proliferation of T24 relative to HBDEC cells. Taken together, metabolic reprogramming of cancer appears central to the tumor selective action of betulinic acid.

**Conclusions:** These findings support the anti-cancer action of betulinic acid on bladder cancer and implicate the role of metabolic reprogramming in the tumor selective action of betulinic acid in melanoma and other cancers. Findings warrant future testing in mouse models of superficial bladder cancer.

**Funding:** NIH R01 DK117884, NCI RA263243, NCI R01 CA251341

---

**Abstract 31**

**Large opioid prescription following cystectomy increases the risk of chronic opioid use**

Christopher Stumierski, Michelle Yu, Danielle Sharbaugh, Michael Stencel, John Myrpo, Benjamin Davies, Jonathan Xobes, Bruce Jacobs

‘Division of Health Services Research, Department of Urology,UPMC, Pittsburgh, PA;’Division of Internal Medicine, Department of Medicine, UPMC, Pittsburgh, PA

**Introduction:** Chronic opioid use following any urologic procedure is known to be as high as 10.8%. Identifying patients at highest risk for chronic use, especially following major surgery, can direct further attention to helping combat this issue. This study aims to evaluate both patient and hospital factors predisposing to persistent opioid use following cystectomy using the Surveillance, Epidemiology, and End Results (SEER) Program.

**Methods:** We identified patients who underwent cystectomy between July 2007 and December 2015 using SEER. The primary outcomes were postoperative opioid use and chronic opioid use, defined as an opioid prescription filled 0–30 days and 90–180 days after surgery, respectively. Multivariable logistic regressions evaluated patient and hospital factors for their contribution to chronic opioid use, as well as opioid prescription postoperatively.

**Results:** A total of 1774 patients were identified who underwent cystectomy during the study period. The majority were opioid-naïve at the time of surgery (70.9%). Procedures were performed at 349 different hospitals. Most were associated with a training program (53.3%) and voluntary non-profit facilities (72.2%), with a median capacity of 361 beds (IQR 234–517). Of patients who filled a postoperative prescription, the median oral morphine equivalent filled during the first month following surgery was 40.0 equivalents (IQR 30.0–60.0). Younger, healthier patients who were exposed to opioids preoperatively were more likely to be prescribed an opioid. Government hospitals were associated with lower likelihood of an opioid prescription; 10.2% of patients in the cohort developed chronic use. Opioid-naïve patients were less likely to develop chronic opioid use relative to non-opioid-naïve patients (OR 0.23, p<0.001). Additionally, an increase in initial opioid prescription by 50 morphine milligram equivalents nearly doubled the risk of developing chronic opioid use (OR 1.98, p<0.001).
**Hospital size, ownership, and affiliation with a medical school were not predictive of chronic use (Figure 1).**

**Conclusions:** Even when controlling for preoperative opioid use, larger prescriptions postoperatively were predictive of chronic opioid use after cystectomy. While opioid prescription may be necessary after major procedures, efforts to reduce the amount prescribed may help to prevent the development of chronic use.

**Funding:** Shadyside Hospital Foundation

---

**Abstract 32**

Prebiotics improve the efficacy of anti-PD1 immunotherapy in bladder cancer by modulating the gut microbiota

Jalal Laaraj1,2,3, Gabriel Lachance1,2, Prisca Nadège Kone1,3, Typhaine Gris1, Afshin Jamshidi1,2,3, Paul Taren1,2, Yves Fradet1,2, Alain Bergeron1,2, Karine Robitaille1,3, Vincent Fradet1,2,3

1Laboratoire d’Uro-Oncologie Expérimentale, Oncology Axis, Centre de recherche du CHU de Québec-Université Laval and Centre de Recherche sur le Cancer de l’Université Laval, Quebec, QC, Canada; 2Institut sur la nutrition et aliments fonctionnels (INAF) et centre NUTRISS, Université Laval, Quebec, QC, Canada

**Introduction:** In multiple cancers, the anti-tumor activity of the immune checkpoint blockade immunotherapies (ICB), such as anti-PD1, is modulated by the gut microbiota. Accordingly, microbiome-based interventions are emerging strategies to modulate the gut microbiota of non-responding patients and enhance the efficacy of ICB. Here, we assessed the modulatory effect of promising prebiotics on the gut microbiota and on improving the efficacy of anti-PD1 in a syngeneic bladder cancer (BCa) mouse model.

**Methods:** Six- to eight-week-old C3H mice were subcutaneously injected with MBT-2 syngeneic tumor cells of BCa and daily fed with eight promising prebiotics. After tumor implantation, mice were injected intraperitoneally with anti-PD1 or an isotype control intraperitoneally, and tumor growth was regularly monitored. To assess the modulatory effect of prebiotics on gut microbiota, mice fecal samples were collected throughout the experiment and subjected to 16S rRNA gene sequencing to profile the gut microbiota composition. Short-chain fatty acids (SCFAs) analysis was performed at sacrifice from mice cecum using gas chromatography coupled with flame ionization detection to assess the impact of prebiotic supplementation on the production of gut microbial-derived metabolites. Finally, peripheral blood mononuclear cells (PBMC) and tumors were collected at sacrifice to assess the immunomodulatory effect of prebiotic supplementation by flow cytometry analysis.

**Results:** Prebiotics A and B (pre_A and pre_B) significantly reduced tumor growth and improved survival of MBT-2-injected mice. The combination of pre_A with anti-PD1 also enhanced anti-PD1 efficacy. Mice treated with pre_A displayed an enrichment of the Bacteroides genus, while mice that received pre_B showed enrichment of Faecalibaculum genus and the Lachnospiraceae family. SCFAs analysis showed that pre_B increased the production of iso-butyric and iso-valeric acids, suggesting a potential mechanism of action in this BCa mouse model. Flow cytometry analysis of PBMC demonstrated that pre_A increased...
Abstract 33
Enrichment for adverse pathology in resected small renal masses that meet objective progression criteria during active surveillance
Muhammad Altok, Arun Menon, Ahmed Aly, Tashinna White, James Gaybrielle, Bo Xu, Michael Petroziello, Charles Roche, Eric Kaufman
Roswell Park Comprehensive Cancer Center, Buffalo, NY

Introduction: Active surveillance (AS) is increasingly used in small renal mass (SRM) patients; however, there is no uniform agreement on specific tumor progression criteria to trigger delayed intervention (DI). Ideal progression criteria for intervention (PCI) would selectively treat SRM with adverse pathology (15–25% of all SRM); however, patient factors (e.g., anxiety) have been the most common trigger for DI to date, which has challenged studying the efficacy of specific PCI thresholds. Recently, we described our AS experience prospectively using predefined PCI to almost exclusively trigger DI. The current study aimed to characterize pathologic outcomes of DI resection cases to assess the efficacy of these PCI thresholds for selecting SRM with adverse pathology.

Methods: From January 2013 to April 2021, all patients with SRM seen at a cancer center were recommended AS if predefined PCI were absent, and DI was recommended only upon new PCI development. PCI was defined prospectively as any SRM-related symptoms, unfavorable biopsy histology, cT3a stage, or any of the following without benign neoplastic biopsy histology: longest tumor diameter (LTD) >4 cm; growth rate >5 mm/year for LTD ≤3 cm or >3 mm/year for LTD >3 cm. Rates of adverse pathology were retrospectively assessed in DI resections and stratified by specific PCI thresholds met.

Results: Of 255 SRM patients with 42 months median followup on AS, there were no metastases and new PCI was diagnosed in 70 (28%), of which 49 (70%) resections and stratified by specific PCI thresholds met.

Conclusions: When the proportion of circulating CD8+ T lymphocytes, supporting a strong antitumor immune response. Similarly, the administration of antibiotics in combination with pre-A reduced its anti-tumor activity and decreased the proportion of circulating CD8+ T lymphocytes, confirming that pre-A activity is gut microbiota dependent.

Conclusions: Taken together, our findings suggest that the modulation of gut microbiota with a diet-based strategy can reduce tumor growth and improve the efficacy of anti-PD1 immunotherapy in BCA. Translation of these findings into clinical practice could potentially overcome the resistance to ICB in BCA patients.

Abstract 34
Outcomes of active surveillance for young and healthy patients with small renal masses
Muhammad Altok, Arun Menon, Ahmed Aly, Tashinna White, James Gaybrielle, Bo Xu, Michael Petroziello, Charles Roche, Eric Kaufman
Roswell Park Comprehensive Cancer Center, Buffalo, NY

Introduction: Reported outcomes for active surveillance (AS) in patients with small renal masses (SRM) are heavily biased towards older and unhealthier patients. The safety, tolerability, and delayed intervention (DI) rates for AS in younger and healthier SRM patients remain largely unexplored. Here, we report outcomes at a single center for SRM patients with estimated life expectancy (LE) >20 years who were managed with AS ± DI.

Methods: From January 2013 to April 2021, all patients with non-hereditary SRM presenting to a single urologic oncologist at a National Comprehensive Cancer Network institute were recommended AS if predefined progression criteria for intervention (PCI) were absent at presentation. PCI was defined prospectively as any SRM-related symptoms, unfavorable biopsy histology, cT3a stage, or either of the following without benign neoplastic biopsy histology: longest tumor diameter (LTD) >4 cm; growth rate >5 mm/year for LTD ≤3 cm or >3 mm/year for LTD >3 cm. DI was considered during AS only upon PCI development. Patients with LE >20 years were retrospectively reviewed. LE was estimated using social security LE estimations adjusted by age, gender, and Charlson comorbidity index. The three- and five-year rates of PCI-freedom and DI-freedom were determined.

Results: Among 98 consecutive SRM patients with LE >20 years, 97 (99%) patients (110 SRMs) did not meet PCI at presentation (median age 57, IQR 47–61) and underwent AS. With median followup of 47 months, 31/97 (32%) AS patients developed PCI of whom 25/31 (81%) underwent DI (all surgery). One (1%) AS patient crossed over to DI without PCI development. Three- and five-year PCI-free rates were 69% and 60%, respectively, and three- and five-year DI-free rates were 76% and 65%, respectively. No patient developed metastasis.

Conclusions: AS using predefined PCI in otherwise unselected SRM patients is well-tolerated and allows most SRM patients with >20 years LE to avoid treatment beyond five years. Long-term DI rates and oncologic safety in younger/healthier patients require further study.

Abstract 35
Partial nephrectomy drives the association between high-volume...
Oncology – Bladder, Renal, Testes

Abstract 36
Investigating the role of SLURP-2 in bladder cancer
Anirban Ganguly, Stephanie Daugherty, Keara Healy, Pradeep Tyagi, Jonathan Beckel
University of Pittsburgh, Pittsburgh, PA

Introduction: The treatment of bladder cancer involves a partial or complete resection of the urinary bladder, which can lead to serious quality of life issues for bladder cancer patients. Hence, better treatment options are needed. Smoking is a major risk factor for bladder cancer, as cigarettes contain nicotine and its metabolites. Nicotinic acetylcholine receptors (nAChRs) play a significant role in bladder cancer development. The urothelium expresses two main types of nAChRs: α3 heteromeric receptors and α7 homomeric receptors. The third type, heteromeric αβ receptors, are also expressed in urothelial cancer. Hence, role of endogenous nAChR modulators known as the human-secreted Ly-6/uPAR-related proteins (SLURPs) deserve special importance. Among the SLURPs, SLURP-2 is antagonist for α3/α4 receptors. Herein, we investigate the role of SLURP-2 as an inhibitor in the progression of bladder cancer.

Methods: Cell culture: T24 bladder transitional carcinoma cells and TRT-HU1 non-cancerous human urothelial cells were cultured in McCoy’s 5a medium supplemented with 10% FBS and KSFM media supplemented with bovine pituitary extract and epidermal growth factor, respectively. MTT assay: Cells were plated on 96 well plates at a concentration of 5000 cells/well and allowed to grow overnight. The cells were then treated with increasing amounts of recombinant SLURP-2 for 24 hours. IC50 was determined by MTT assay. qPCR: mRNA was extracted from T24 and TRT-HU1 cells. Following reverse transcription, qPCR was performed to compare expression levels of SLURP-2 between the two cell types. SLURP-2 expression was normalized to the expression of a housekeeping gene (18S rRNA) and relative expression calculated using the 2-ΔΔCt method.

Results: MTT assay: The IC50 for SLURP-2 was five times lower in T24 bladder cancer cell lines (1.04 µg/ml) compared to the TRT-HU1 cell lines (5 µg/ml). qPCR: SLURP-2 expression was found to be downregulated in T24 bladder cancer cell lines by 50%.

Conclusions: Preliminary results suggest a cytotoxic role for SLURP-2 in bladder cancer. Future mechanistic as well as in vivo studies on the role of SLURP-2 in mouse models of bladder cancer are required.

Funding: NIH R01DK117884

Abstract 36. Figure 1.
Abstract 37

Genitourinary malignancies in patients presenting with microscopic hematuria: Northwestern Ontario study
Northern Ontario School of Medicine, Thunder Bay, ON, Canada

Introduction: This study aimed to determine the incidence and characteristics of genitourinary (GU) malignancy in patients that presented with microscopic hematuria (MH) at our tertiary center. Our institution is the only facility providing urologic care to the region of Northwestern Ontario (land area=526 417.35 km², population=232 299).

Methods: We conducted a retrospective cohort study of all patients that presented to our center with MH from March 2017 to March 2021. The inclusion criteria included patients aged >40 years, with two microscopic urine analyses at referral showing >3 RBCs/HPF that had at least a single cystoscopy and imaging of the upper urinary tract at, or before the first urology visit.

All patients were followed for a minimum of six months with repeat microscopic urine analyses. Low- and high-grade MH were defined as <25 RBCs/HPF and >25 RBCs/HPF respectively.

Results: A total of 2545 patients (49.1% males) aged 63.1±17.4 years were included. During the entire study period, the incidence of GU malignancy was 5.2%, including bladder (4.3%), kidney (0.7%), and ureteric (0.2%) cancer. During the initial evaluation, the incidence of GU cancer was 4.2%. Forty patients (1.7%) underwent ureteroscopy after initial evaluation due to positive urine cytology and/or suspicious upper tract imaging, of which, five patients (0.2%) were found to have urothelial tumors. When stratified by the grade of MH at initial evaluation, 3.1% and 10.3% of patients in the low- and high-grade MH groups were found to have GU malignancy, respectively (p=0.0006). Our study identified 1812 patients that were followed up for three years. The rate of GU malignancy among this cohort was 4.5% and 12.5% in patients with low- and high-grade MH, respectively. Interestingly, only two-thirds (59 patients) of individuals in the low-grade MH group that were cancer-positive had a GU malignancy diagnosis during the initial workup.

Conclusions: The prevalence of GU malignancy in patients with MH is currently underestimated in the Canadian guidelines. Among our patients, 5.2% were diagnosed with GU malignancy over the study period. Repeat workup is specifically recommended for individuals with low-grade MH, as we found that one-third of cancer-positive patients had a missed cancer diagnosis during the initial workup.

Abstract 38

Patient characteristics associated with genitourinary tract malignancies in microscopic hematuria cases: A single Canadian center experience
Northern Ontario School of Medicine, Thunder Bay, ON, Canada

Introduction: The aim of our study was to investigate the characteristics of patients with and without genitourinary malignancy who were referred to the urology service with microscopic hematuria.

Methods: We conducted a retrospective data analysis for all patients who presented to the urology service of Thunder Bay Regional Health Science Centre with microscopic hematuria (MH) over the last five years. Inclusion criteria were patients aged >40 years old, with microscopic urine analysis at referral (>3 RBCs/HPF), that had at least a single cystoscopy and imaging to the upper urinary tract at or before the first urology visit and were followed for at least six months with repeat microscopic urine analysis. Low- and high-grade MH was described as <25 RBCs/HPF and >25 RBCs/HPF, respectively. Logistic regression models were fit for baseline clinical characteristics and care level characteristics, with reporting in odds ratios and 95% confidence intervals. Outcome measures were binary occurrences of any genitourinary malignancy, and a separate analysis was performed on the outcome of malignancy grade (low-high).

Results: The retrospective analysis included 2545 patients referred for urology services included in the study, with 1102 (43.3%) males and a mean age of 66.48 (SD 12.82). Genitourinary cancers were detected in 129 (5.1%) of patients, with 43 (29.9%) patients with high-grade cancer. Covariates that reached statistical significance for increased odds of genitourinary cancers in logistic regression models were age (OR 1.03, p<0.01), gender (male) (OR 2.96, p<0.01), previous gross hematuria (OR 3.46, p<0.01), lower urinary tract symptoms (OR 0.08, p=0.013), and high grade of MH (>25RBC/HPF) (OR 2.97, p<0.01). For the grade of cancer outcome, male gender (OR 5.66, p<0.01), previous gross hematuria (OR 3.87, p<0.01), and family history of GU cancer (OR 6.54, p<0.02) were associated with an increased odd of high-grade GU cancers.

Conclusions: The prevalence of genitourinary malignancy in patients presenting with MH is currently underestimated. Along with age, male gender, previous family history of GU cancer, and previous history of gross hematuria, we highlight the association of high grade of MH (RBC > 25 RBC/HPF).

Abstract 39

Clinical practice patterns and genitourinary tract malignancies in microscopic hematuria patients: A Northwestern Ontario perspective
Northern Ontario School of Medicine, Thunder Bay, ON, Canada

Introduction: Microscopic hematuria (MH) can be the earliest sign of genitourinary (GU) cancers. Therefore, the early detection of GU cancers hinges on patient flow in the healthcare system. This study’s goal was to investigate the association of clinical practice patterns (i.e., time to access health services) with the GU cancer in patients referred for MH.

Methods: We conducted a retrospective chart review of patients presented to the urology service at Thunder Bay Regional Health Science Centre with MH from 2017–2022. The differences between the two time points in the patient evaluation were reported as follows: T1= date of first UA-date of consultation received; T2= date of urology first visit-date of consultation received; T3= date of cystoscopy-date of urology first visit.

Results: The retrospective analysis included 2545 patients referred for urology services included in the study, with 1102 (43.3%) males and a mean age of 66.48 (SD 12.82). Statistically significant associated factors with genitourinary cancer detection rate were age (OR 1.03, p<0.01), male gender (OR 2.42, p<0.01), cytology results (OR 3.25, p<0.01), anuria high-grade MH (OR 2.80, p<0.01), and other imaging (OR 7.97, p<0.01). For the grade of cancer outcomes, associated factors included male sex (OR 1.59, p<0.01), number of ordered cytology (OR 6.10, p<0.01), cytology results (OR 8.03, p<0.01), and anuria very high-grade MH (OR 0.05, p=0.04). We found that time points in patient evaluation, longer-T1, T2, and T3 were associated with more cancer detection rates and worse outcomes. When it comes to the grade of cancer, those who were living further had higher grades of cancer.

Conclusions: Both patient- and system-level factors interact to provide high-quality care in GU cancers among patients with MH. Our findings highlight the primary care practice in tandem with urology healthcare services at higher levels (hospital) can affect the detection rate and grade of GU cancers in MH patients.